Anhydrous Intra-Oral Soft Anticholinergic Esters for Sialorrhea
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anticholinergic agents used to treat sialorrhea, such as glycopyrrolate, suffer from significant systemic side effects due to their ability to cross the blood-brain barrier and systemic absorption, limiting their therapeutic index and dosage.
Innovation Solution
Development of soft anticholinergic esters, specifically formulated as anhydrous intra-oral compositions, which rapidly metabolize into inactive metabolites upon entering systemic circulation, minimizing systemic side effects while maintaining localized efficacy in treating sialorrhea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional anticholinergic agents like glycopyrrolate are used to treat sialorrhea, then saliva production is reduced, but systemic side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of anticholinergic agents through esterification, transforming them into soft drugs with altered pharmacokinetic properties. The esterified compounds have reduced systemic bioavailability and faster metabolism, changing the parameter of drug persistence in the body while maintaining local anticholinergic activity for saliva reduction
Solution Approach 2:
The patent uses esterification as a chemical intermediary transformation. The ester group acts as a mediator that temporarily masks the pharmacologically active amine, reducing systemic absorption and side effects, while allowing local action at the site of application. The ester bond serves as a reversible blocking group that can be hydrolyzed to release the active drug when needed
2Productivity
If higher doses of anticholinergics are administered to improve sialorrhea treatment, then drooling reduction increases, but adverse effects worsen
Solution Approach 1:
The patent changes the pharmacokinetic parameters of anticholinergic drugs by converting them to esterified soft drugs. This transformation maintains the therapeutic parameter of drooling reduction while modifying the toxicity parameter through reduced systemic exposure and faster elimination, allowing effective dosing without proportionally increasing adverse effects
3Reliability
If locally active anticholinergics are administered to reduce systemic side effects, then therapeutic index improves, but dosage limitation remains
Solution Approach 1:
The patent applies parameter changes by modifying the molecular properties of anticholinergics through esterification, changing their absorption, distribution, metabolism, and excretion characteristics. The esterified forms have altered permeability and metabolic stability parameters that enable higher local dosing with reduced systemic exposure, improving the therapeutic index without strict dosage limitations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The soft anticholinergic esters provide effective reduction of saliva production for up to six hours with reduced systemic side effects, comparable to glycopyrrolate, and a clinically significant three-point improvement in drooling reduction using modified Teacher's Drooling Scale.
Implementation Method 1
these novel muscarinic antagonists, just as all other soft drugs, are designed to elicit their intended pharmacological effect at the site of application, but to be quickly metabolized into their designed-in, inactive metabolite upon entering the systemic circulation
Data Source
AI summary
Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic ester is provided in an effective amount or concentration in an anhydrous intra-oral formulation that can inhibit excessive drooling resulting from a condition known as sialorrhea.